ADAR1 Capital Management LLC Takes $16.59 Million Position in Inhibikase Therapeutics, Inc. (NYSE:IKT)

ADAR1 Capital Management LLC bought a new position in shares of Inhibikase Therapeutics, Inc. (NYSE:IKT) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 5,103,005 shares of the company’s stock, valued at approximately $16,585,000. Inhibikase Therapeutics makes up 3.3% of ADAR1 Capital Management LLC’s investment portfolio, making the stock its 8th biggest holding. ADAR1 Capital Management LLC owned 7.36% of Inhibikase Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Separately, Blair William & Co. IL raised its stake in shares of Inhibikase Therapeutics by 7.0% in the 4th quarter. Blair William & Co. IL now owns 134,953 shares of the company’s stock valued at $439,000 after purchasing an additional 8,833 shares during the period. 3.81% of the stock is owned by institutional investors.

Inhibikase Therapeutics Stock Down 6.8 %

NYSE IKT opened at $1.84 on Monday. The firm’s 50 day moving average is $2.35 and its 200-day moving average is $2.43. The company has a market capitalization of $136.79 million, a PE ratio of -0.69 and a beta of 1.02. Inhibikase Therapeutics, Inc. has a 12-month low of $1.12 and a 12-month high of $4.20.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “neutral” rating on shares of Inhibikase Therapeutics in a research report on Friday, March 28th.

About Inhibikase Therapeutics

Inhibikase Therapeutics, Inc, a clinical-stage pharmaceutical company, develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract.